-
Top Narrow Based Indexes For August 30
Tuesday, August 30, 2011 - 10:33am | 199By 10:30 am, the Dow Jones Industrial Average was down 66.64 points, or 0.58%, to 11,472.61, while the broader Standard & Poor's 500 index had dropped 9.47 points, or 0.78%. The NASDAQ composite index fell 11.46 points, or 0.45%. Some of the narrow based indexes that are still afloat in the...
-
Notable Call Options Activity in Novavax
Tuesday, August 30, 2011 - 10:12am | 93Shares of Novavax (NASDAQ: NVAX) are higher on the session by 17.26%, currently trading at $1.97. The stock has been moving largely lower over the past three months, but it is currently trading above the 50-day moving average. Options traders are focusing on calls today. A short while ago the...
-
Piper Jaffray Comments On Flat IMS Sales And Impact On Human Genome Sciences
Tuesday, August 30, 2011 - 8:57am | 69According to Piper Jaffray, Human Genome Sciences (NASDAQ: HGSI) is impacted by flat IMS sales. Piper Jaffray said that IMS reported July Benlysta sales of $5.0mn, down from $5.2mn in June. “Our price target of $18 is based on a 1-year forward P/E multiple of 40x our 2015 fully taxed non-GAAP EPS...
-
Wedbush Reaffirms Outperform on Cepheid
Tuesday, August 30, 2011 - 8:57am | 86Wedbush is out with its report today on Cepheid (NASDAQ: CPHD), reaffirming Outperform. In its report, Wedbush writes, "Reaffirming OUTPERFORM rating and $45 PT. The positive 2Q11 inflection and more recent signal gives us comfort with the 2011 instrument placement opportunity, TB rollout, and...
-
Pre-Market Movers
Tuesday, August 30, 2011 - 8:53am | 105Dole Foods (NASDAQ: DOLE) trades over 8% higher in pre-market trading. Universal Display Corp (NASDAQ: PANL) trades over 5% higher after the company said it has entered into a technology license agreement with Panasonic Idemitsu OLED Lighting Co. Central European Distribution Corp (NASDAQ: CEDC)...
-
Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130
Tuesday, August 30, 2011 - 8:32am | 115Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency. The results show that AEZS-130 reached its primary endpoint demonstrating >90% area-under-the-curve...
-
Wedbush Adds Cepheid To Best Ideas List
Tuesday, August 30, 2011 - 8:05am | 28Wedbush Securities has added Cepheid (NASDAQ: CPHD) to its Best Ideas List and maintains its Outperform rating and $45 price target.
-
Bionovo Announces Positive Results of the Tolerability Trial of Menerba for Menopausal Hot Flashes
Tuesday, August 30, 2011 - 8:00am | 144Bionovo, Inc. (NASDAQ: BNVI) today announced the positive results from the completion of their tolerability trial of Menerba™ (MF101) for menopausal hot flashes. The open-label, randomized, clinical trial of Menerba was conducted at four U.S. clinical sites. Postmenopausal women between the ages...
-
UPDATE: Bank Of America Raises Price Target On Seattle Genetics To $19
Tuesday, August 30, 2011 - 7:37am | 94According to Bank of America, Seattle Genetics (NASDAQ: SGEN) price target is raised to $19. Bank of America said that it is increasing its PO from $17 to $19 after finding that the prior model double-counted dilutive options. “Our corrected model assumes 11% dilution from outstanding options and...
-
Aeterna Zentaris Announces Results of its Novel Orally Active Anticancer Erk Inhibitor at the American Chemical Society National Meeting
Tuesday, August 30, 2011 - 7:30am | 157Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado. The poster was presented...
-
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR in Patients with Non-Cancer Pain
Tuesday, August 30, 2011 - 7:02am | 77Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration has accepted for filing a supplemental New Drug Application for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection to treat opioid-induced...
-
ZIOPHARM Oncology Announces First Patient Dosed in Phase I Study of ZIN ATI-001 in Advanced Melanoma
Tuesday, August 30, 2011 - 6:57am | 106ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma. ZIN ATI-001 is the second clinical oncology product candidate from the ZIOPHARM-...
-
Bank of America Raises PO On Seattle Genetics To $19
Tuesday, August 30, 2011 - 6:14am | 28Bank of America has raised the price objective on Seattle Genetics (NASDAQ: SGEN) from $17 to $19 and maintains its Buy rating.
-
PharmAthene Says It Is Company's Policy Not to Comment on Market Rumors
Monday, August 29, 2011 - 3:01pm | 116PharmAthene, Inc. (NYSE: PIP) announced today that in view of the relatively large increase in the price of its stock at the end of the trading day on August 25, 2011, the NYSE Amex has contacted the Company in accordance with its usual practice. It is the Company's policy not to comment on market...
-
Celsion Scream Higher; Breaks Through Resistance
Monday, August 29, 2011 - 2:54pm | 126Shares of Celsion (NASDAQ: CLSN) are moving higher today; currently, shares are up by 9.78%, trading at $3.48. The stock has been consolidating below the 20-day and 50-day moving averages for the past few weeks; CLSN has now firmly broken through those resistance levels. Celsion now needs to...